Hepatic veno-occlusive disease in ataxia-telangiectasia

Journal of Pediatrics

Volumn 134, Issue 6, 1999, Pages 786-788

  Srisirirojanakorn, Nitikul ^a   Finegold, Milton J ^a   Gopalakrishna, G S ^a   Klish, William J ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b TEXAS CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ARTICLE; ATAXIA TELANGIECTASIA; BONE MARROW TRANSPLANTATION; CASE REPORT; CLINICAL FEATURE; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; HEPATITIS B; HEPATITIS C; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER VENOOCCLUSIVE DISEASE; MALE; PRIORITY JOURNAL; SCHOOL CHILD;

EID: 0033511294     PISSN: 00223476     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-3476(99)70301-X     Document Type: Article

References (14)

1. 1. Gatti RA, Boder E, Vinters HV, Sparkes RS, Norman A, Lange K. Ataxia-telangiectasia: an interdisciplinary approach to pathogenesis. Medicine 1991;70:99-116.
2. 2. Ament M. Gastrointestinal manifestations of immunodeficiency diseases in infants, children, and adults. In: Targan SR, Shanahan F, editors. Immunology and immunopathology of the liver and gastrointestinal tract. Los Angeles: IGAKU-SHOIN; 1996. p. 338-9.
3. 3. Omaha E, Ikuta F. Ataxia-telangiectasia: immunocytochemical demonstration of α-fetoprotein and hepatitis B surface antigen in the liver. Acta Neuropathol (Berl) 1982;56:13-6.
4. 4. Muller H. Recessively inherited deficiencies predisposing to cancer. Anticancer Res 1990;10:513-8.
5. 5. Pillsbury LH, Peters SM, Wientzen RL, Phillips T, Papadopoulou ZL, Bellanti JA. Ataxia-telangiectasia: immunologically mediated renal and hepatic failure. Ann Allergy 1985;55: 539-40,593-8.
6. 6. Amromin GD, Boder E, Teplitz R. Ataxia-telangiectasia with a 32 year survival. A clinicopathological report. J Neuropathol Exp Neurol 1979;38: 621-43.
7. 7. Casaril M, Gabrielli GB, Capra F, Falezza GC. Ataxia telangiectasia. Description of a case with multiple cerebral hemorrhages and liver cirrhosis. Minerva Med 1982;73:2183-8.
8. 8. Waldmann TA, McIntire KR. Serum-alpha-fetoprotein levels in patients with ataxia-telangiectasia. Lancet 1972;2: 1112-5.
9. 9. Schafer DF, Sorrell MF. Vascular disease of the liver. In: Feldman M, Sleisenger MH, Scharschmidt BF, editors. Gastrointestinal and liver disease. 6th ed. Philadelphia: Mosby; 1998. p. 1191-2.
10. 10. Stricker BHCh, Biour M, Wilson JHP. Individual agents: drugs. In: Stricker BHCh, editor. Drug-induced hepatic injury. 2nd ed. Amsterdam: Elsevier; 1992. p. 270-5.
11. 11. Farrell GC. Liver disease caused by anticancer drugs. In: Farrell GC, editor. Drug-induced liver disease. Edinburgh: Churchill Livingstone; 1994. p. 481-2.
12. 12. Bashir RM, Lewis JH. Hepatotoxicity of drugs used in the treatment of gastrointestinal disorders. Gastroenterol Clin North Am 1995;24:937-67.
13. 13. Maller ES, Mascarenhas MR. Systemic conditions affecting the liver. In: Walker WA, Durie PR, Hamilton JR, et al, editors. Pediatric gastrointestinal disease. St Louis: Mosby; 1996. p. 1296-7.
14. 14. Etzioni A, Benderly A, Rosenthal E, et al. Defective humoral and cellular immune functions associated with venoocclusive disease of the liver. J Pediatr 1987;110:549-54.